Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Triple-Negative Breast Cancer|High-grade Serous Ovarian Cancer|Solid Tumors|NUT Midline Carcinoma
Interventions: DRUG: CUDC-907
Sponsor: Curis, Inc.